TCR2 Therapeutics (TCRR) PT Raised to $57 at Wedbush, Following Earnings
- Nasdaq, S&P 500, set records as jobless claims decline
- Moderna (MRNA) Tops Q2 Street Estimates, Nabs $4.2 Billion from 199 Million Sold Vaccines That Yielded 93% Efficacy Through Six Months
- Oil rises over 1% as Mideast tensions face virus concerns
- Penn National Gaming (PENN) 'Scores' with $2 Billion Deal to Acquire theScore (SCR), Seen as 'Highly Strategic'
- Uber (UBER) Beats Estimates As Higher Labor Spend Drags on Profitability, Analysts Lower PTs but Remain Bullish
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $57.00 (from $55.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TCR2 Therapeutics (TCRR) PT Lowered to $44 at BMO Capital, Following Earnings
- KE Holdings (BEKE) PT Lowered to $35 at Goldman Sachs
- Dine Brands (DIN) PT Lowered to $118 at Truist Securities
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!